|
PennyStockChaser.com: Pennystockchaser.com: www.pennnystockchaser.com: Penny Stock Chaser Alerts, December 15, 2009: CALD, HGSI, SFSF and ASFI
Dec 15, 2009 (M2 PRESSWIRE via COMTEX) --
Pennystockchaser.com Alerts include Callidus Software Inc. (NASDAQ: CALD); Human Genome Sciences, Inc. (Nasdaq: HGSI); SuccessFactors, Inc. (Nasdaq: SFSF) and Asta Funding, Inc. (Nasdaq: ASFI)
-- December 15, 2009 Callidus Software Inc. (NASDAQ: CALD) trading at $2.85 on a volume of 93,272 shares
Callidus Software Expands in the African Market With Seven Seas Technologies
Market-Leader Grows Partner Eco-System to Deliver Sales Performance Management in Africa
SAN JOSE, CA, Dec 15, 2009 -- Callidus Software Inc. (NASDAQ: CALD), the leader in Sales Performance Management (SPM), continuing the momentum of its global partner eco-system, today announced a partnership with Seven Seas Technologies, a leading provider of integrated business and technology solutions. Under the agreement, Seven Seas Technologies will resell, implement and support Callidus Software's sales performance management solutions in Africa.
About Callidus Software(R)
Callidus Software (www.callidussoftware.com) (NASDAQ: CALD) is the market and technology leader in Sales Performance Management (SPM). Callidus' customers gain a competitive advantage by maximizing sales cost efficiencies and driving improvements in sales execution. Our award-winning Software-as-a-Service (SaaS) applications set the standard for performance management across the sales force. Over 2 million employees and channel partners have their performance managed by Callidus Software.
-- December 15, 2009 Human Genome Sciences, Inc. (Nasdaq: HGSI) trading at $28.48 on a volume of 1.18M shares.
Human Genome Sciences Announces Submission of Marketing Authorization Application to EMEA for JOULFERON(R) (ZALBIN(TM))
ROCKVILLE, Md., Dec 15, 2009 -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON(R) (albinterferon alfa-2b, known in the United States as ZALBIN(TM)) for the treatment of chronic hepatitis C. In November 2009, HGS submitted a Biologics License Application (BLA) for ZALBIN to the FDA in the United States.
About Human Genome Sciences
The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat lupus, hepatitis C, inhalation anthrax and cancer.
-- December 15, 2009 SuccessFactors, Inc. (Nasdaq: SFSF) trading at $16.80 on a volume of 744,514 shares
SuccessFactors and PricewaterhouseCoopers Japan Officially Partner to Deliver the Largest Business Execution Powerhouse Team
--Partnership to Result in Driving Business Performance and Executing of Executive Strategy
TOKYO, Dec 15, 2009 -- SuccessFactors, Inc. (Nasdaq: SFSF), the global leader in business execution software, announced a joint partnership between SuccessFactors Japan and PricewaterhouseCoopers Japan (PwC). The joint partnership will help Japanese organisations drive improved business execution and represents one of the largest Human Capital Management (HCM) consulting partnerships in Japan.
About SuccessFactors, Inc.
SuccessFactors is the global leader in Business Execution Software. The SuccessFactors Business Execution Suite improves business alignment and people performance for companies of all sizes. More than 5 million users and 2,800 companies use SuccessFactors every day. For more information, visit: www.successfactors.com.
-- December 15, 2009 Asta Funding, Inc. (Nasdaq: ASFI) closed at $8.43 on a volume of 70,630 shares.
Asta Funding, Inc. to Report Fourth Quarter and Year End 2009 Results
ENGLEWOOD CLIFFS, N.J., Dec 15, 2009 -- Asta Funding, Inc. (Nasdaq: ASFI), a consumer receivable asset management and liquidation firm, will report its financial results for the fourth quarter and fiscal year ended September 30, 2009 after the close of the market on Tuesday, December 15, 2009. The company will file Form 12b-25 on December 15, 2009 for a brief extension of its reporting deadline.
About Asta Funding:
Based in Englewood Cliffs, NJ, Asta Funding, Inc., is a consumer receivable asset management company that specializes in the purchase, management and liquidation of performing and non-performing consumer receivables. For additional information, please visit our website at http://www.astafunding.com.
About PennyStockChaser.com
PennyStockChaser.com's alerts are daily e-mail on stocks that are hot in the market. These include stocks with huge volume, penny stocks, new 52 weeks high or lows, stocks with technical indicators and much more. Our stock alerts have done very well in the last couple of weeks.
PennyStockChaser.com is a leading stock website that provides free daily alerts on stocks that are moving up. PennyStockChaser.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at editorial@pennystockchaser.com
PennyStockChaser.com is an independent electronic publication that provides information on selected publicly traded companies. PennyStockChaser.com is not a registered investment advisor or broker-dealer. PennyStockChaser.com's affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
CONTACT: PennyStockChaser Editorial Staff
e-mail: editorial@pennystockchaser.com
WWW: http://pennystockchaser.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
[ Back To CaaS Homepage's Homepage ]
|
CaaS Whitepapers 
